BioCentury
ARTICLE | Emerging Company Profile

Tolerance Bio: Rejuvenating the thymus

Starting with congenital athymia, former Provention Bio team aims to restore immune tolerance — with broader implications for lifespan extension

January 15, 2026 9:01 PM UTC

The Provention Bio team is back as Tolerance Bio for a second round of tackling immune tolerance, this time going upstream of T cells with therapies designed to preserve thymus function. While its first goal is to treat congenital athymia, the Philadelphia-based biotech believes the approach could extend healthy lifespan more broadly.

The thymus is a small gland located in the upper chest. During early life, the thymus trains T cells to recognize the difference between the body’s own tissues (self) and foreign invaders (non-self) so that the immune system knows what to attack and what to leave unharmed...